June 18, 2008
Lexapro is the Leading Single Agent In First- and Second-Line Patient Share for the Treatment of Generalized Anxiety Disorder
WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Lexapro is the leading single agent used in anxiety therapy with 11.7 percent and 14.9 percent of first- and second-line patient share, respectively. According to surveyed psychiatrists and primary care physicians (PCPs), Lexapro is distinguished by its superior safety and tolerability profile; physicians specifically mention that the drug's low risk of drug-drug interactions is another key advantage. These advantages are critical to Lexapro's lead in patient share over generically available agents such as sertraline, citalopram, paroxetine and fluoxetine.
According to the new report entitled Treatment Algorithms in Generalized Anxiety Disorder, 90 percent and 85 percent of surveyed psychiatrists and PCPs, respectively, state that the presence of comorbid depression influences them to prescribe a selective serotonin reuptake inhibitor (SSRI) and 81 percent and 71 percent of surveyed psychiatrists and PCPs, respectively, state that SSRIs are effective for psychic and somatic anxiety symptoms. These opinions underscore the advantages of SSRIs in anxiety treatment: these agents address both major components of anxiety symptoms and are effective for the most common comorbid condition of generalized anxiety disorder (GAD) patients, major depression.
"Although SSRIs are the most commonly used drug class for the treatment of GAD, physicians continue to favor benzodiazepines as well, despite the potential for addiction. In addition, serotonin-norepinephrine reuptake inhibitors, non-benzodiazepine GABA-A agonist sleep aids such as Ambien and Lunesta, anti-epileptic drugs and atypical antipsychotics all have their niches in GAD therapy," said Nathan Calloway, analyst at Decision Resources.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithm Insight Series provides the following:
-- Summary of U.S. medical practice based on interviews with leading experts in the field -- Qualitative diagnosis/referral/treatment algorithm for the U.S. -- Drug usage by lines of therapy (1st, 2nd, 3rd line) -- Discussion of key freeform combinations by lines of therapy -- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line) -- Progression of therapy from key 1st line products -- Pathway to key therapies from previous therapies -- Qualitative analysis of two-year forecast incorporating upcoming launches, changes in reimbursement, etc About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 [email protected]
Contact: Elizabeth Marshall of Decision Resources, +1-781-296-2563,[email protected]
Web site: http://www.decisionresources.com/